tocilizumab for COVID-19: a live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results	deaths E	clinical improvement E	death or ventilation E
COVID-19 mild to moderate meta-analysis
CORIMUNO-19, 2020 NCT04331808		RCT	tocilizumab	standard of care	COVID-19 mild to moderate	some concern	64/67	inconclusive
EMPACTA, 2020 NCT04372186		RCT	tocilizumab	placebo	COVID-19 mild to moderate	some concern	259/129	conclusif
Capra, 2020		OBS	tocilizumab	control	COVID-19 mild to moderate	critical	62/23	suggested

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis